Singula Bio develops neoantigen-based cell therapies that utilize the patient's immune system to target and eliminate solid tumors, including difficult-to-treat malignancies like ovarian cancer. The company provides personalized treatment options aimed at preventing cancer recurrence and improving patient survival rates.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Solid tumors, including malignancies like ovarian cancer, pose significant treatment challenges and often lead to recurrence and reduced patient survival rates. Current cancer treatment methods may not always be effective in preventing cancer recurrence in these difficult-to-treat tumors.
Solution
Singula Bio is developing individualized cell therapies that leverage a patient's own immune system to target and eliminate solid tumors. Their approach focuses on identifying neoantigens specific to each patient's tumor, which are then used to create personalized cell therapies. These therapies aim to prevent cancer recurrence and improve long-term survival by selectively targeting and destroying cancer cells while minimizing damage to healthy tissue. Singula Bio combines immunological, medical, surgical, and computational technologies to develop these selective therapies.
Target Audience
The primary target audience includes cancer patients with solid tumors, particularly those with difficult-to-treat malignancies like ovarian cancer, and the oncologists treating them.
Features
- Neoantigen identification using advanced immunological and computational techniques
- Patient-specific cell therapy development for personalized treatment
- Selective targeting of cancer cells to minimize off-target effects
- Focus on difficult-to-treat solid malignancies, such as ovarian cancer
- Technologies combining cancer medicine, immunology, cell/molecular biology, computational biology, and surgery